Kura Oncology enters $330M upfront collaboration with Kyowa Kirin for ziftomenib; potential milestones up to $1.491B

Kura Oncology, Inc.

Upfront payment of $330M to Kura; near-term milestones up to $420M including launch of monotherapy R/R setting.
Additional milestones of $513M for hematologic malignancies, plus up to $228M if field expansion option for solid tumors is exercised.
Kyowa Kirin to lead ex-US development/commercialization; Kura leads US with joint profit/cost sharing on US commercialization.
Kura retains rights to next-generation menin inhibitors outside oncology field; exclusivity obligations for both parties.
Tiered double-digit royalties on ex-US sales of ziftomenib on a country-by-country basis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.